12508 Federal Register / Vol. 77, No. 41 / Thursday, March 1, 2012 / Proposed Rules 

Authority for This Rulemaking 

Title 49 of the United States Code 

specifies the FAA’s authority to issue 

rules on aviation safety. Subtitle I, 

section 106, describes the authority of 

the FAA Administrator. Subtitle VII: 

Aviation Programs, describes in more 

detail the scope of the Agency’s 

authority. 

We are issuing this rulemaking under 

the authority described in subtitle VII, 

part A, subpart III, section 44701: 

‘‘General requirements.’’ Under that 

section, Congress charges the FAA with 

promoting safe flight of civil aircraft in 

air commerce by prescribing regulations 

for practices, methods, and procedures 

the Administrator finds necessary for 

safety in air commerce. This regulation 

is within the scope of that authority 

because it addresses an unsafe condition 

that is likely to exist or develop on 

products identified in this rulemaking 

action. 

Regulatory Findings 

We determined that this proposed AD 

would not have federalism implications 

under Executive Order 13132. This 

proposed AD would not have a 

substantial direct effect on the States, on 

the relationship between the national 

Government and the States, or on the 

distribution of power and 

responsibilities among the various 

levels of government. 

For the reasons discussed above, I 

certify this proposed regulation: 

(1) Is not a ‘‘significant regulatory 

action’’ under Executive Order 12866, 

(2) Is not a ‘‘significant rule’’ under 

the DOT Regulatory Policies and 

Procedures (44 FR 11034, February 26, 

1979), 

(3) Will not affect intrastate aviation 

in Alaska, and 

(4) Will not have a significant 

economic impact, positive or negative, 

on a substantial number of small entities 

under the criteria of the Regulatory 

Flexibility Act. 

List of Subjects in 14 CFR Part 39 

Air transportation, Aircraft, Aviation 

safety, Incorporation by reference, 

Safety. 

The Proposed Amendment 

Accordingly, under the authority 

delegated to me by the Administrator, 

the FAA proposes to amend 14 CFR part 

39 as follows: 

PART 39—AIRWORTHINESS 

DIRECTIVES 

1. The authority citation for part 39 

continues to read as follows: 

Authority: 49 U.S.C. 106(g), 40113, 44701. 

§ 39.13 [Amended] 

2. The FAA amends § 39.13 by adding 

the following new airworthiness 

directive (AD): 

The Boeing Company: Docket No. FAA– 

2012–0187; Directorate Identifier 2011– 

NM–094–AD. 

(a) Comments Due Date 

We must receive comments by April 30, 

2012. 

(b) Affected ADs 

None. 

(c) Applicability 

This AD applies to The Boeing Company 

Model 757–200, –200PF, –200CB, and –300 

series airplanes; certificated in any category; 

for which compliance with 14 CFR 

121.1117(d), 125.509(d), or 129.117(d) is not 

required; regardless of the date of issuance of 

the original certificate of airworthiness or 

export airworthiness approval. 

(d) Subject 

Joint Aircraft System Component (JASC)/ 

Air Transport Association (ATA) of America 

Code 7397: Engine fuel system wiring. 

(e) Unsafe Condition 

This AD was prompted by fuel system 

reviews conducted by the manufacturer. We 

are issuing this AD to prevent development 

of an ignition source inside the center fuel 

tank caused by a latent in-tank failure 

combined with electrical energy transmitted 

into the center fuel tank via the fuel quantity 

indicating system (FQIS) wiring due to a 

single out-tank failure. 

(f) Compliance 

Comply with this AD within the 

compliance times specified, unless already 

done. 

(g) Modification 

Within 60 months after the effective date 

of this AD, modify the FQIS wiring or fuel 

tank systems to prevent development of an 

ignition source inside the center fuel tank, in 

accordance with a method approved by the 

Manager, Seattle Aircraft Certification Office 

(ACO), FAA. 

Note 1 to paragraph (g) of this AD: After 

accomplishment of the actions required by 

paragraph (g) of this AD, maintenance and/ 

or preventive maintenance under 14 CFR part 

43 is permitted provided the maintenance 

does not result in changing the AD-mandated 

configuration (reference 14 CFR 39.7). 

(h) Optional Installation of Flammability 

Reduction Means 

As an alternative to the requirements of 

paragraph (g) of this AD, operators may elect 

to comply with the requirements of 14 CFR 

121.1117 or 14 CFR 125.509 or 14 CFR 

129.117 (not including the exclusion of cargo 

airplanes in Sections 121.1117(j), 129.117(j), 

and 125.509(j)). Following this election, 

failure to comply with Sections 121.1117, 

129.117, and 125.509 is a violation of this 

AD. 

(i) Alternative Methods of Compliance 

(AMOCs) 

(1) The Manager, Seattle ACO, FAA, has 

the authority to approve AMOCs for this AD, 

if requested using the procedures found in 14 

CFR 39.19. In accordance with 14 CFR 39.19, 

send your request to your principal inspector 

or local Flight Standards District Office, as 

appropriate. If sending information directly 

to the manager of the ACO, send it to the 

attention of the person identified in the 

Related Information section of this AD. 

Information may be emailed to: 9-ANMSeattle-ACO-AMOC-Requests@faa.gov. 

(2) Before using any approved AMOC, 

notify your appropriate principal inspector, 

or lacking a principal inspector, the manager 

of the local flight standards district office/ 

certificate holding district office. 

(j) Related Information 

For more information about this AD, 

contact Tak Kobayashi, Aerospace Engineer, 

Propulsion Branch, ANM–140S, FAA, Seattle 

Aircraft Certification Office (ACO), 1601 Lind 

Avenue SW., Renton, Washington 98057– 

3356; phone: 425–917–6499; fax: 425–917– 

6590; email: takahisa.kobayashi@faa.gov. 

Issued in Renton, Washington, on February 

21, 2012. 

Ali Bahrami, 

Manager, Transport Airplane Directorate, 

Aircraft Certification Service. 

[FR Doc. 2012–4931 Filed 2–29–12; 8:45 am] 

BILLING CODE 4910–13–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

21 CFR Part 1308 

[Docket No. DEA–345] 

Schedules of Controlled Substances: 

Placement of Five Synthetic 

Cannabinoids Into Schedule I 

AGENCY: Drug Enforcement 

Administration, Department of Justice. 

ACTION: Notice of proposed rulemaking. 

SUMMARY: The Drug Enforcement 

Administration (DEA) proposes placing 

five synthetic cannabinoids 1-pentyl-3- 

(1-naphthoyl)indole (JWH–018), 1-butyl3-(1-naphthoyl)indole (JWH–073), 1-[2- 

(4-morpholinyl)ethyl]-3-(1- 

naphthoyl)indole (JWH–200), 5-(1,1- 

dimethylheptyl)-2-(3- 

hydroxycyclohexyl)-phenol (CP– 

47,497), and 5-(1,1-dimethyloctyl)-2-(3- 

hydroxycyclohexyl)-phenol 

(cannabicyclohexanol, CP–47,497 C8 

homologue) including their salts, 

isomers, and salts of isomers whenever 

the existence of such salts, isomers, and 

salts of isomers is possible, into 

Schedule I of the Controlled Substances 

Act (CSA). This proposed action is 

pursuant to the CSA which requires that 


srobinson on DSK4SPTVN1PROD with PROPOSALS
Federal Register / Vol. 77, No. 41 / Thursday, March 1, 2012 / Proposed Rules 12509 

1 21 CFR 1300.01. 

such actions be made on the record after 

opportunity for a hearing through 

formal rulemaking. 

DATES: DEA will permit interested 

persons to file written comments on this 

proposal pursuant to 21 CFR 1308.43(g). 

Electronic comments must be submitted 

and written comments must be 

postmarked on or before April 30, 2012. 

Commenters should be aware that the 

electronic Federal Docket Management 

System will not accept comments after 

midnight Eastern Time on the last day 

of the comment period. 

Interested persons, defined as those 

‘‘adversely affected or aggrieved by any 

rule or proposed rule issuable pursuant 

to section 201 of the Act (21 U.S.C. 

811),’’ 1 may file a request for hearing or 

waiver of participation pursuant to 21 

CFR 1308.44 and in accordance with 21 

CFR 1316.45. Requests for hearing and 

waivers of participation must be 

received on or before April 2, 2012. 

ADDRESSES: To ensure proper handling 

of comments, please reference ‘‘Docket 

No. DEA–345’’ on all electronic and 

written correspondence. DEA 

encourages all comments be submitted 

electronically through http:// 

www.regulations.gov using the 

electronic comment form provided on 

that site. An electronic copy of this 

document and supplemental 

information to this proposed rule are 

also available at the http:// 

www.regulations.gov Web site for easy 

reference. Paper comments that 

duplicate the electronic submission are 

not necessary as all comments 

submitted to www.regulations.gov will 

be posted for public review and are part 

of the official docket record. Should 

you, however, wish to submit written 

comments via regular or express mail, 

they should be sent to the Drug 

Enforcement Administration, Attention: 

DEA Federal Register Representative/ 

OD, 8701 Morrissette Drive, Springfield, 

VA 22152. All requests for hearing and 

waivers of participation must be sent to 

Drug Enforcement Administration, 

Attention: Hearing Clerk/LJ, 8701 

Morrissette Drive, Springfield, VA 

22152. 

FOR FURTHER INFORMATION CONTACT: 

Alan G. Santos, Associate Deputy 

Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration; Mailing Address: 8701 

Morrissette Drive, Springfield, Virginia 

22152; Telephone: (202) 307–7165. 

SUPPLEMENTARY INFORMATION: 

Posting of Public Comments: Please 

note that all comments received are 

considered part of the public record and 

made available for public inspection 

online at http://www.regulations.gov 

and in the DEA’s public docket. Such 

information includes personal 

identifying information (such as your 

name, address, etc.) voluntarily 

submitted by the commenter. 

If you want to submit personal 

identifying information (such as your 

name, address, etc.) as part of your 

comment, but do not want it to be 

posted online or made available in the 

public docket, you must include the 

phrase ‘‘PERSONAL IDENTIFYING 

INFORMATION’’ in the first paragraph 

of your comment. You must also place 

all of the personal identifying 

information you do not want posted 

online or made available in the public 

docket in the first paragraph of your 

comment and identify what information 

you want redacted. 

If you want to submit confidential 

business information as part of your 

comment, but do not want it to be 

posted online or made available in the 

public docket, you must include the 

phrase ‘‘CONFIDENTIAL BUSINESS 

INFORMATION’’ in the first paragraph 

of your comment. You must also 

prominently identify confidential 

business information to be redacted 

within the comment. If a comment has 

so much confidential business 

information that it cannot be effectively 

redacted, all or part of that comment 

may not be posted online or made 

available in the public docket. 

Personal identifying information and 

confidential business information 

identified and located as set forth above 

will be redacted, and the comment, in 

redacted form, will be posted online and 

placed in the DEA’s public docket file. 

Please note that the Freedom of 

Information Act applies to all comments 

received. If you wish to inspect the 

agency’s public docket file in person by 

appointment, please see the FOR

FURTHER INFORMATION CONTACT

paragraph. 

Request for Hearing or Waiver of 

Participation in Hearing 

In accordance with the provisions of 

the CSA (21 U.S.C. 811(a)), this action 

is a formal rulemaking ‘‘on the record 

after opportunity for a hearing.’’ Such 

proceedings are conducted pursuant to 

the provisions of the Administrative 

Procedure Act (5 U.S.C. 556 and 557) 

and 21 CFR 1308.41. Pursuant to 21 CFR 

1308.44(a) and (c), requests for hearing 

and waivers of participation may be 

submitted only by interested persons, 

defined as those ‘‘adversely affected or 

aggrieved by any rule or proposed rule 

issuable pursuant to section 201 of the 

Act (21 U.S.C. 811).’’ Requests for 

hearing must conform to the 

requirements of 21 CFR 1308.44(a) and 

1316.47. A request should state, with 

particularity, the interest of the person 

in the proceeding and the objections or 

issues, if any, concerning which the 

person desires to be heard. Any waiver 

must conform to the requirements of 21 

CFR 1308.44(c), including a written 

statement regarding the interested 

person’s position on the matters of fact 

and law involved in any hearing. 

Please note that pursuant to 21 U.S.C. 

811(a), the purpose and subject matter 

of the hearing is restricted to ‘‘(A) 

find[ing] that such drug or other 

substance has a potential for abuse, and 

(B) mak[ing] with respect to such drug 

or other substance the findings 

prescribed by subsection (b) of section 

812 of this title for the schedule in 

which such drug is to be placed * * *’’ 

Requests for hearing and waivers of 

participation in the hearing should be 

submitted to DEA using the address 

information provided above. 

Legal Authority 

The DEA implements and enforces 

Titles II and III of the Comprehensive 

Drug Abuse Prevention and Control Act 

of 1970, often referred to as the 

Controlled Substances Act and the 

Controlled Substances Import and 

Export Act (21 U.S.C. 801–971), as 

amended (hereinafter, ‘‘CSA’’). The 

implementing regulations for these 

statutes are found in Title 21 of the 

Code of Federal Regulations (CFR), parts 

1300 to 1321. Under the CSA, controlled 

substances are classified in one of five 

schedules based upon their potential for 

abuse, their currently accepted medical 

use, and the degree of dependence the 

substance may cause. 21 U.S.C. 812. The 

initial schedules of controlled 

substances by statute are found at 21 

U.S.C. 812(c) and the current list of 

scheduled substances are published at 

21 CFR Part 1308. 

The CSA permits these initial 

schedules to be modified by providing 

that scheduling of any drug or other 

substance may be initiated by the 

Attorney General (1) on his own motion; 

(2) at the request of the Secretary of 

HHS, or (3) on the petition of any 

interested party. 21 U.S.C. 811(a). The 

Attorney General may, by rule, ‘‘add to 

such a schedule or transfer between 

such schedules any drug or other 

substance if he (A) finds that such drug 

or other substance has a potential for 

abuse, and (B) makes with respect to 

such drug or other substance the 

findings prescribed by subsection (b) of 

section 812 of this title for the schedule 

in which such drug is to be placed 

* * *’’ 


srobinson on DSK4SPTVN1PROD with PROPOSALS
12510 Federal Register / Vol. 77, No. 41 / Thursday, March 1, 2012 / Proposed Rules 

2This Notice of Intent was corrected on January 

13, 2011. 76 FR 2287. 

3Note that ‘‘marihuana’’ is the spelling originally 

used in the Controlled Substances Act (CSA). This 

document uses the spelling that is more common 

in current usage, ‘‘marijuana.’’ 

4 DEA received separate Evaluations and 

Recommendation documents from HHS with 

respect to each of the five synthetic cannabinoids. 

HHS recommended Schedule I placement for each 

of these five substances on the following dates: 1- 

pentyl-3-(1-naphthoyl)indole (JWH–018) (January 5, 

2012); 1-pentyl-3-(1-naphthoyl)indole (JWH–073) 

and 1-[2-(4-morpholinyl)ethyl]-3-(1- 

naphthoyl)indole (JWH–200) (February 6, 2012), 5- 

(1,1-dimethylheptyl)-2-[(1R,3S)-3- 

hydroxycyclohexyl]-phenol (CP–47,497) and 5-(1,1- 

dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]- 

phenol (cannabicyclohexanol) (February 13, 2012). 

5Comprehensive Drug Abuse Prevention and 

Control Act of 1970, H.R. Rep. No. 91–1444, 91st 

Cong., Sess. 1 (1970); 1970 U.S.C.C.A.N. 4566, 4601. 

Background 

On November 24, 2010, DEA 

published a Notice of Intent 2 to 

temporarily place five synthetic 

cannabinoids into Schedule I pursuant 

to the temporary scheduling provisions 

of the CSA: 1-pentyl-3-(1- 

naphthoyl)indole (JWH–018), 1-butyl-3- 

(1-naphthoyl)indole (JWH–073), 1-[2-(4- 

morpholinyl)ethyl]-3-(1- 

naphthoyl)indole (JWH–200), 5-(1,1- 

dimethylheptyl)-2-(3- 

hydroxycyclohexyl)-phenol (CP– 

47,497), and 5-(1,1-dimethyloctyl)-2-(3- 

hydroxycyclohexyl)-phenol 

(cannabicyclohexanol, CP–47,497 C8 

homologue). 75 FR 71635. Following 

this, on March 1, 2011, the 

Administrator published a Final Order 

in the Federal Register amending 21 

CFR 1308.11(g) to temporarily place the 

five synthetic cannabinoids into 

Schedule I of the CSA pursuant to the 

temporary scheduling provisions of 21 

U.S.C. 811(h). 76 FR 11075. This Final 

Order, which became effective on the 

date of publication, was based on 

findings by the Administrator that the 

temporary scheduling of the five 

synthetic cannabinoids was necessary to 

avoid an imminent hazard to the public 

safety. The CSA (21 U.S.C. 811(h)(2)) 

requires that the temporary scheduling 

of a substance expire at the end of one 

year from the date of issuance of the 

order. However, if proceedings to 

schedule a substance pursuant to 21 

U.S.C. 811(a) are pending, the 

temporary scheduling of a substance 

may be extended for up to six months. 

Under this provision, the temporary 

scheduling of the cannabinoids, which 

would expire on February 29, 2012, may 

be extended to August 29, 2012. This 

extension is being ordered by the 

Administrator in a separate action. 

As described in the March 1, 2011 

Final Order, a ‘‘cannabinoid’’ is a class 

of chemical compounds in the 

marijuana 3 plant that are structurally 

related. The cannabinoid D9- 

tetrahydrocannabinol (THC) is the 

primary psychoactive constituent of 

marijuana. ‘‘Synthetic cannabinoids’’ 

are a large family of chemically 

unrelated structures functionally 

(biologically) similar to THC, the active 

principal of marijuana. 

The emergence of these five synthetic 

cannabinoids represents a recent 

phenomenon in the U.S. designer drug 

market. Numerous products, marketed 

under the guise being ‘‘herbal incense,’’ 

with trade names such as ‘‘Spice’’ and 

‘‘K2’’ have conclusively been found to 

contain these five substances. These 

products are manufactured by spiking 

plant material with the synthetic 

cannabinoids and then distributed in a 

way that poses dangerous consequences 

to the consumer. Marketed as ‘‘legal’’ 

alternatives to marijuana, these products 

are being abused for their psychoactive 

properties and are packaged without 

information as to their health and safety 

risks. 

Proposed Determination To Schedule 

Five Synthetic Cannabinoids 

This NPRM proposes the permanent 

scheduling of JWH–018, JWH–200, 

JWH–073, CP–47,497 and 

cannabicyclohexanol pursuant to 21 

U.S.C. 811(a)(1). On June 21, 2011, DEA 

requested a scientific and medical 

evaluation and scheduling 

recommendation from the Assistant 

Secretary of HHS for each of the five 

synthetic cannabinoids pursuant to 21 

U.S.C. 811(b). Upon receipt and 

evaluation of the scientific and medical 

evaluation and scheduling 

recommendations from the Assistant 

Secretary,4 DEA concluded its analysis 

of all other relevant data for the 

proposal to place JWH–018, JWH–200, 

JWH–073, CP–47,497 and 

cannabicyclohexanol into Schedule I of 

the CSA. 

Included below is a brief summary of 

each factor as analyzed by HHS and 

DEA, and as considered by DEA in the 

scheduling decision. Please note that 

both the DEA and HHS analyses are 

available under ‘‘Supporting and 

Related Material’’ of the public docket 

for this proposed rule at 

www.regulations.gov under docket 

number DEA–345. 

1. The Drug’s Actual or Relative 

Potential for Abuse: The abuse potential 

of the five synthetic cannabinoids under 

evaluation is associated with their 

ability to evoke cannabinoid-like 

subjective effects similar to those 

evoked by the Schedule I cannabinoid 

delta-9-tetrahydrocannabinol (THC). 

The legislative history of the CSA 

provides four factors to consider in 

determining whether a particular drug 

or substance has potential for abuse: 5

i. There is evidence that individuals 

are taking the drug or other substance in 

amounts sufficient to create a hazard to 

their health or to the safety of other 

individuals or to the community; or 

ii. There is significant diversion of the 

drug or substance from legitimate drug 

channels; or 

iii. Individuals are taking the drug or 

drugs containing such a substance on 

their own initiative rather than on the 

basis of medical advice from a 

practitioner licensed by law to 

administer such drugs in the course of 

his professional practice; or 

iv. The drug is a new drug so related 

in its action to a drug or other substance 

already listed as having a potential for 

abuse to make it likely that the drug or 

other substance will have the same 

potential for abuse as such drugs, thus 

making it reasonable to assume that 

there may be significant diversion from 

legitimate channels, significant use 

contrary to or without medical advice, 

or that it has a substantial capability of 

creating hazards to the health of the user 

or to the safety of the community. 

With respect to the first factor, a 

number of case reports and case series 

(article grouping several case reports) 

have shown that individuals are taking 

these substances and products 

containing these substances in amount 

sufficient to induce toxic effects similar 

to those induced by marijuana such as 

anxiety, tachycardia and hallucinations. 

Severe toxic effects including seizures, 

tachyarrhythmias, extreme anxiety 

leading to suicide and the precipitation 

of psychotic episodes have also been 

reported following abuse of these 

substances or products containing these 

substances. 

In considering evidence of significant 

diversion of the drug or substance from 

legitimate drug channels under the 

second factor, it must be noted that as 

of March 1, 2011, these synthetic 

cannabinoids have been temporarily 

controlled as Schedule I substances and 

thus have not been legally available 

unless for research purposes. The 

National Forensic Laboratory 

Information System (NFLIS) details over 

5,450 reports from state and local 

forensic laboratories identifying JWH– 

018, JWH–073, JWH–200, CP–47,497 or 

cannabicyclohexanol in drug related 

exhibits for a period from January 2009 

to December 2011 from 39 states. The 

System to Retrieve Information from 

Drug Evidence (STRIDE) also details 


srobinson on DSK4SPTVN1PROD with PROPOSALS
Federal Register / Vol. 77, No. 41 / Thursday, March 1, 2012 / Proposed Rules 12511 

reports from federal forensic 

laboratories identifying JWH–018, JWH– 

073, and JWH–200 in drug related 

exhibits for a period from January 2009 

to December 2011. 

For the third factor, there is no 

currently accepted medical use for any 

of the five synthetic cannabinoids, and, 

outside of an extremely limited research 

setting, no medical practitioner is 

currently licensed by law to administer 

them. Thus, with no accepted medical 

use or administering practitioners, any 

individuals currently taking using 

products containing JWH–018, JWH– 

073, JWH–200, CP–47,497 or 

cannabicyclohexanol are doing so on 

their own initiative without medical 

advice from a practitioner licensed to 

administer those substances. 

Related to the fourth factor, HHS 

states that JWH–018, JWH–073, JWH– 

200, CP–47,497 and 

cannabicyclohexanol are cannabinoids 

with a potential for abuse similar to the 

Schedule I substances marijuana and 

THC. These synthetic cannabinoids 

appear to be marketed solely for abuse 

of their marijuana-like activity and 

because, prior to the March 1, 2011 

Final Order, they were not controlled 

under the CSA. As such, commerce 

involving these synthetic cannabinoids 

can only be for the purposes of abuse 

and escaping the regulatory and 

criminal penalties of the CSA that 

pertain to marijuana. 

JWH–018, JWH–200, JWH–073, CP– 

47,497 and cannabicyclohexanol have 

agonist properties at the CB1 receptor. 

The CB1 receptors are thought to be 

responsible for the euphoric and 

psychoactive effects of THC and related 

cannabinoids. 

Drug discrimination is a method in 

which laboratory animals indicate 

whether a test drug produces physical 

or psychic perceptions similar to those 

produced by a known drug of abuse. 

Drug discrimination studies in rats 

suggest that JWH–018, JWH–200, JWH– 

073, CP–47,497, and 

cannabicyclohexanol have similar 

subjective effects as THC, while 

numerous anecdotal self-reports, as well 

as case reports and case series 

substantiate that these substances and 

their associated products are abused by 

humans for their hallucinogenic effects. 

An indication of the extent of such 

abuse may be found in the results of the 

2011 Monitoring the Future survey of 

high schools students, where 1 in 9 high 

school seniors (11.4%) reported having 

used ‘‘synthetic marijuana’’ (products 

often containing synthetic 

cannabinoids) in the past year. These 

statistics make it one of the most 

frequently mentioned among high 

school seniors, second only to 

marijuana. Additionally, while products 

containing synthetic cannabinoids 

appear to produce subjective effects 

similar to marijuana, they are dissimilar 

to other licit and illicit drugs. 

As evidence of abuse on the national 

scale, State public health and poison 

centers have issued warnings in 

response to adverse health effects 

associated with abuse of herbal incense 

products containing these synthetic 

cannabinoids. These adverse effects 

included tachycardia, elevated blood 

pressure, unconsciousness, tremors, 

seizures, vomiting, hallucinations, 

agitation, anxiety, pallor, numbness and 

tingling. This is in addition to the 

numerous public health and poison 

centers which have similarly issued 

warnings regarding the abuse of these 

synthetic cannabinoids and their 

associated products, and the ban on the 

use of these synthetic cannabinoids by 

military personnel issued in response to 

reported instances of abuse by active 

personnel. 

2. Scientific Evidence of the Drug’s 

Pharmacological Effects, If Known: In 

their recommendations for the 

placement of the five synthetic 

cannabinoids, HHS states that in vitro 

and preclinical studies suggest that the 

pharmacological effects of JWH–018, 

JWH–200, JWH–073, CP–47,497 and 

cannabicyclohexanol are similar to 

those of THC. 

The CB1 receptors are thought to be 

responsible for the euphoric and 

psychoactive effects of THC and related 

cannabinoids. JWH–018, JWH–200, 

JWH–073, CP–47,497 and 

cannabicyclohexanol have agonist 

properties at the CB1 receptor. 

Animal studies also provided 

evidence of cannabinoid-like 

pharmacological effects of these 

synthetic cannabinoids. JWH–018, 

JWH–200, CP–47,497 and 

cannabicyclohexanol were shown to be 

active in all four parameters of the 

mouse tetrad, a well-established 

paradigm for evaluating substances for 

cannabimimetic properties, while JWH– 

073 was only tested, and shown to be 

active, in three of the four parameters of 

the tetrad test. JWH–018, JWH–200, 

JWH–073, CP–47,497 and 

cannabicyclohexanol substitute fully for 

the discriminative stimulus effects of 

THC in laboratory animals, suggesting 

that they are likely to have similar 

subjective effects as THC, the main 

active ingredient of marijuana. 

3. The State of Current Scientific 

Knowledge Regarding the Drug or Other 

Substance: The appearance of these 

substances in the designer drug market 

can be traced to the initial forensic 

laboratory confirmation in midDecember 2008. A commercial 

laboratory in Frankfurt, Germany 

announced the identification of JWH– 

018 in samples of herbal incense and 

others were identified shortly after this 

initial determination. 

These five cannabinoid substances 

have been termed ‘synthetic’ or ‘nonclassical’ because they are agonists at 

the CB1 receptor but are structurally 

distinct from naturally occurring 

cannabinoids. 

HHS has confirmed to DEA in a letter 

dated November 22, 2010, that there are 

no Investigational New Drug 

Applications (INDs) or New Drug 

Applications (NDAs) for these synthetic 

cannabinoids. DEA is also not aware of 

any accepted medical use for these five 

synthetic cannabinoids. 

4. Its History and Current Pattern of 

Abuse: Synthetic cannabinoids have 

been developed over the last 30 years to 

investigate their cannabimimetic 

properties and as research tools to 

investigate the cannabinoid systems 

(Huffman et al., 1994; Wiley et al., 

1998). Trafficking of synthetic 

cannabinoids was first reported in the 

United States in a December 2008 

encounter, where a shipment of ‘Spice’ 

was seized and analyzed by U.S. 

Customs and Border Patrol in Dayton, 

Ohio. Around the same time, in 

December 2008, JWH–018 and 

cannabicyclohexanol were identified by 

German forensic laboratories (EMCDDA, 

2009). 

JWH–018, JWH–073, JWH–200, CP– 

47,497, and Cannabicyclohexanol have 

been found alone and found laced on 

products that are marketed as herbal 

incense. The abuse of these substances 

and their associated products for their 

psychoactive effects has been widely 

reported and their popularity has spread 

rapidly since December 2008. The 

NFLIS has detailed over 5,450 reports 

from state and local forensic laboratories 

identifying JWH–018, JWH–073, JWH– 

200, CP–47,497 and/or 

cannabicyclohexanol in drug related 

exhibits for a period from January 2009 

to December 2011 from 39 states. Prior 

to being temporarily placed in Schedule 

I on March 1, 2011, these products were 

promoted as legal alternatives to 

marijuana, were widely available over 

the Internet, and were found to be sold 

in gas stations, convenience stores, 

tobacco and head shops to all 

populations. 

As of January 13, 2012, forty-eight 

states in the U.S. as well as numerous 

local jurisdictions and countries have 

controlled at least one of these five 

synthetic cannabinoids. 


srobinson on DSK4SPTVN1PROD with PROPOSALS
12512 Federal Register / Vol. 77, No. 41 / Thursday, March 1, 2012 / Proposed Rules 

5. The Scope, Duration, and 

Significance of Abuse: HHS states that 

the current scope and duration of use of 

the synthetic cannabinoids is likely 

underestimated because of the lack of 

widely available toxicological methods 

to identify its use using routine analyses 

(Peters and Martinez-Ramirez 2010). 

Additionally, since these substances 

were never intended for human 

consumption, minimal information 

exists as to the health implications 

resulting from exposure to these 

substances (Griffiths et al., 2010; 

Vardakou et al., 2010). As forensic 

procedures and toxicology screens are 

being developed, the amount of 

information concerning these 

substances and the associated products 

is increasing. 

The abuse of synthetic cannabinoids 

has been associated with both acute and 

long-term public health and safety 

concerns. In the past year, increased 

exposure incidents have been 

documented by poison control centers 

in the United States. As of December 31, 

2011, the American Association of 

Poison Centers (AAPCC) has reported 

receiving 9,992 calls corresponding to 

products purportedly laced with 

synthetic cannabinoids. The calls 

represented exposed individuals from 

all 50 states and the District of 

Columbia, as well as a few calls 

regarding exposed individuals in Puerto 

Rico, U.S. Territories, foreign countries, 

and a category identified as ‘‘overseas/ 

US military/diplomatic.’’ Several of 

these exposures were confirmed to 

involve JWH–018 (141), and JWH–073 

(12). 

The increased abuse of these synthetic 

cannabinoids in the United States is 

supported by an increasing number of 

encounters by law enforcement. Over 

the past year in the United States there 

has been a significant increase in 

availability, trafficking and abuse of 

these substances as evident from the 

increasing number of encounters 

reported by forensic laboratories (NFLIS 

and STRIDE data). Product 

manufacturing and synthesis 

laboratories have been discovered, and 

laboratories have been found 

manufacturing products by lacing plant 

material with synthetic cannabinoids. 

6. What, if any, Risk There is to the 

Public Health: Law enforcement, 

military, and public health officials 

have reported exposure incidents that 

demonstrate the dangers associated with 

these substances to both the individual 

abusers and other affected individuals. 

Two suicides, one also involving a 

murder, have been linked to the abuse 

of synthetic cannabinoids (law 

enforcement communication to DEA). 

Warnings regarding the dangers of 

synthetic cannabinoid abuse and 

associated products have been issued by 

numerous state public health 

departments and poison centers and 

private organizations. Detailed product 

analyses describe variations in the 

amount and type of synthetic 

cannabinoid laced on the plant material; 

this is true even within samplings of the 

same product. 

Because they share pharmacological 

similarities with the Schedule I 

substance THC, the synthetic 

cannabinoids JWH–018, JWH–073, 

JWH–200, CP–47,497, and 

cannabicyclohexanol pose substantial 

risks to the abuser. Numerous 

emergency department admissions have 

been connected to these substances, 

while law enforcement communications 

to DEA indicate multiple violent 

episodes linked to smoking these 

synthetic cannabinoids. Health 

warnings issued by numerous state 

public health departments and poison 

centers have described adverse health 

effects associated with smoking 

(inhaling) these products, including 

agitation, vomiting, tachycardia, 

elevated blood pressure, seizures, 

paranoia, hallucinations and nonresponsiveness, and fatality. 

Case reports describe presentations to 

emergency departments of individuals 

exposed to synthetic cannabinoids with 

symptoms that include anxiety and 

panic attacks, tremors, generalized 

convulsions, psychosis, heart 

palpitations and elevated pulse, severe 

gastrointestinal distress, tremors, 

blurred peripheral vision, nausea, and 

persistent vomiting with retching. Such 

abuse also includes instances of persons 

suspected of driving under the influence 

of these synthetic cannabinoids, 

including one incident where an 

automobile was driven through a 

residence. In that case the driver 

claimed to have no memory of the event 

while a toxicology analysis confirmed 

that the driver had smoked a product 

containing JWH–018, but not any other 

drugs. 

7. Its Psychic or Physiological 

Dependence Liability: HHS states that 

the pharmacological profile of JWH– 

018, JWH–200, JWH–073, CP–47,497 

and cannabicyclohexanol strongly 

suggests that they possess physiological 

and psychological dependence liability 

similar to that of the Schedule I 

controlled substances marijuana and 

THC. While no laboratory controlled 

clinical studies of the psychic or 

physical dependence potential of these 

five synthetic cannabinoids are 

currently available, their 

pharmacological profile indicates that 

the substances will have high psychic 

and physiologic dependence capacity. 

Case reports have shown that herbal 

products containing synthetic 

cannabinoids could produce physical 

dependence and a withdrawal 

syndrome. The HHS analysis discusses 

one case report in which the authors 

concluded that the patient satisfied 

criteria for a diagnosis of DSM–IV and 

ICD–10 dependency syndrome on JWH– 

018. Some reported withdrawal 

symptoms included elevated blood 

pressure, restlessness, drug craving, 

nightmares, sweating, nausea, tremor 

and headache. 

Because these substances act through 

the same molecular target as THC, the 

main active ingredient of marijuana, it 

can be reasonably expected that their 

physical dependence liability will be 

similar. Long-term, regular use of 

marijuana can lead to physical 

dependence and withdrawal following 

discontinuation as well as psychic 

addiction or dependence. 

8. Whether the Substance is an 

Immediate Precursor of a Substance 

Already Controlled Under the CSA: 

JWH–018, JWH–073, JWH–200, CP– 

47,497, and cannabicyclohexanol are 

not considered immediate precursors of 

any controlled substance of the CSA as 

defined by Title 21, U.S.C. 802(23). 

Conclusion: Based on consideration of 

the scientific and medical evaluations 

and accompanying recommendations of 

HHS, and based on DEA’s consideration 

of its own eight-factor analyses, DEA 

finds that these facts and all relevant 

data constitute substantial evidence of 

potential for abuse of JWH–018, JWH– 

073, JWH–200, CP–47,497 and 

cannabicyclohexanol. As such, DEA 

hereby proposes to schedule JWH–018, 

JWH–073, JWH–200, CP–47,497 and 

cannabicyclohexanol as controlled 

substances under the CSA. 

Proposed Determination of Appropriate 

Schedule 

The CSA establishes five schedules of 

controlled substances known as 

Schedules I, II, III, IV, and V. The statute 

outlines the findings required to place a 

drug or other substance in any 

particular schedule. 21 U.S.C. 812(b). 

After consideration of the analysis and 

recommendations of the Assistant 

Secretary for Health of HHS and review 

of all available data, the Administrator 

of DEA, pursuant to 21 U.S.C. 812(b)(1), 

finds that: 

(1) 1-pentyl-3-(1-naphthoyl)indole 

(JWH–018), 1-butyl-3-(1- 

naphthoyl)indole (JWH–073), 1-[2-(4- 

morpholinyl)ethyl]-3-(1- 

naphthoyl)indole (JWH–200), 5-(1,1- 

dimethylheptyl)-2-(3- 


srobinson on DSK4SPTVN1PROD with PROPOSALS
Federal Register / Vol. 77, No. 41 / Thursday, March 1, 2012 / Proposed Rules 12513 

hydroxycyclohexyl)-phenol (CP– 

47,497), and 5-(1,1-dimethyloctyl)-2-(3- 

hydroxycyclohexyl)-phenol 

(cannabicyclohexanol, CP–47,497 C8 

homologue) have a high potential for 

abuse; 

(2) 1-pentyl-3-(1-naphthoyl)indole 

(JWH–018), 1-butyl-3-(1- 

naphthoyl)indole (JWH–073), 1-[2-(4- 

morpholinyl)ethyl]-3-(1- 

naphthoyl)indole (JWH–200), 5-(1,1- 

dimethylheptyl)-2-(3- 

hydroxycyclohexyl)-phenol (CP– 

47,497), and 5-(1,1-dimethyloctyl)-2-(3- 

hydroxycyclohexyl)-phenol 

(cannabicyclohexanol, CP–47,497 C8 

homologue) have no currently accepted 

medical use in treatment in the United 

States; and 

(3) there is a lack of accepted safety 

for use of 1-pentyl-3-(1- 

naphthoyl)indole (JWH–018), 1-butyl-3- 

(1-naphthoyl)indole (JWH–073), 1-[2-(4- 

morpholinyl)ethyl]-3-(1- 

naphthoyl)indole (JWH–200), 5-(1,1- 

dimethylheptyl)-2-(3- 

hydroxycyclohexyl)-phenol (CP– 

47,497), and 5-(1,1-dimethyloctyl)-2-(3- 

hydroxycyclohexyl)-phenol 

(cannabicyclohexanol, CP–47,497 C8 

homologue) under medical supervision. 

Based on these findings, the 

Administrator of DEA concludes that 1- 

pentyl-3-(1-naphthoyl)indole (JWH– 

018), 1-butyl-3-(1-naphthoyl)indole 

(JWH–073), 1-[2-(4-morpholinyl)ethyl]- 

3-(1-naphthoyl)indole (JWH–200), 5- 

(1,1-dimethylheptyl)-2-(3- 

hydroxycyclohexyl)-phenol (CP– 

47,497), and 5-(1,1-dimethyloctyl)-2-(3- 

hydroxycyclohexyl)-phenol 

(cannabicyclohexanol, CP–47,497 C8 

homologue), including their salts, 

isomers and salts of isomers, whenever 

the existence of such salts, isomers, and 

salts of isomers is possible, warrant 

control in Schedule I of the CSA (21 

U.S.C. 812(b)(1)). 

Requirements for Handling Five 

Synthetic Cannabinoids 

If this rule is finalized as proposed, 

JWH–018, JWH–200, JWH–073, CP– 

47,497 and cannabicyclohexanol would 

be permanently, as they are currently 

temporarily, subject to the CSA and the 

Controlled Substances Import and 

Export Act (CSIEA) regulatory controls 

and administrative, civil, and criminal 

sanctions applicable to the manufacture, 

distribution, dispensing, importing, and 

exporting of a Schedule I controlled 

substance, including the following: 

Registration. Any person who 

manufactures, distributes, dispenses, 

imports, exports, engages in research or 

conducts instructional activities with 

JWH–018, JWH–200, JWH–073, CP– 

47,497 or cannabicyclohexanols, or who 

desires to manufacture, distribute, 

dispense, import, export, engage in 

research or conduct instructional 

activities with any of the five synthetic 

cannabinoids, would need to be 

registered to conduct such activities 

pursuant to 21 U.S.C. 822 and 958 and 

in accordance with 21 CFR part 1301. 

Security. JWH–018, JWH–200, JWH– 

073, CP–47,497 or cannabicyclohexanol 

would be subject to Schedule I security 

requirements and would need to be 

manufactured, distributed, and stored 

pursuant to 21 U.S.C. 823 and in 

accordance with 21 CFR 1301.71, 

1301.72(a), (c) and (d), 1301.73, 1301.74, 

1301.75(a) and (c), 1301.76. 

Labeling and Packaging. All labels 

and labeling for commercial containers 

of JWH–018, JWH–200, JWH–073, CP– 

47,497 or cannabicyclohexanol which 

are distributed on or after the effective 

date of the finalization of this rule 

would need to be in accordance with 21 

CFR 1302.03–1302.07, pursuant to 21 

U.S.C. 825. 

Quotas. Quotas for JWH–018, JWH– 

200, JWH–073, CP–47,497 and 

cannabicyclohexanol will be established 

based on registrations granted and quota 

applications received pursuant to part 

1303 of Title 21 of the Code of Federal 

Regulations. 

Inventory. Every registrant required to 

keep records and who possesses any 

quantity of JWH–018, JWH–200, JWH– 

073, CP–47,497 or cannabicyclohexanol 

would be required to keep an inventory 

of all stocks of any of the five synthetic 

cannabinoids on hand pursuant to 21 

U.S.C. 827 and in accordance with 21 

CFR 1304.03, 1304.04, and 1304.11. 

Every registrant who desires registration 

in Schedule I for any of the five 

synthetic cannabinoids would be 

required to conduct an inventory of all 

stocks of the substance on hand at the 

time of registration. 

Records. All registrants would be 

required to keep records pursuant to 21 

U.S.C. 827 and in accordance with 21 

CFR 1304.03, 1304.04, 1304.21, 1304.22, 

and 1304.23. 

Reports. All registrants required to 

submit reports pursuant to 21 U.S.C. 

827 and in accordance with 21 CFR 

1304.33 would be required to do so 

regarding JWH–018, JWH–200, JWH– 

073, CP–47,497 and 

cannabicyclohexanol. 

Order Forms. All registrants involved 

in the distribution of JWH–018, JWH– 

200, JWH–073, CP–47,497 or 

cannabicyclohexanol pursuant to 21 

U.S.C. 828 would be required to comply 

with the order form requirements of 21 

CFR 1305. 

Importation and Exportation. All 

importation and exportation of JWH– 

018, JWH–200, JWH–073, CP–47,497 or 

cannabicyclohexanol would need to be 

done in accordance with 21 CFR Part 

1312, pursuant to 21 U.S.C. 952, 953, 

957, and 958. 

Criminal Liability. Any activity with 

JWH–018, JWH–200, JWH–073, CP– 

47,497 or cannabicyclohexanol not 

authorized by, or in violation of, 

Subchapter I Part D and Subchapter II 

of the CSA or the CSIEA occurring on 

or after effective date of the finalization 

of this proposed rule would be 

unlawful. 

Regulatory Analyses 

Executive Orders 12866 and 13563 

In accordance with 21 U.S.C. 811(a), 

this proposed scheduling action is 

subject to formal rulemaking procedures 

done ‘‘on the record after opportunity 

for a hearing,’’ which are conducted 

pursuant to the provisions of 5 U.S.C. 

556 and 557. The CSA sets forth the 

criteria for scheduling a drug or other 

substance. Such actions are exempt 

from review by the Office of 

Management and Budget pursuant to 

Section 3(d)(1) of Executive Order 

12866 and the principles reaffirmed in 

Executive Order 13563. 

Executive Order 12988 

This proposed regulation meets the 

applicable standards set forth in 

Sections 3(a) and 3(b)(2) of Executive 

Order 12988 Civil Justice Reform to 

eliminate ambiguity, minimize 

litigation, establish clear legal 

standards, and reduce burden. 

Executive Order 13132 

This proposed rulemaking does not 

preempt or modify any provision of 

State law; nor does it impose 

enforcement responsibilities on any 

State; nor does it diminish the power of 

any State to enforce its own laws. 

Accordingly, this rulemaking does not 

have federalism implications warranting 

the application of Executive Order 

13132. 

Executive Order 13175 

This proposed rule will not have 

tribal implications and will not impose 

substantial direct compliance costs on 

Indian tribal governments. 

Paperwork Reduction Act of 1995 

This action does not impose a new 

collection of information under the 

Paperwork Reduction Act of 1995, 44 

U.S.C. 3501–3521. 

List of Subjects in 21 CFR Part 1308 

Administrative practice and 

procedure, Drug traffic control, 


srobinson on DSK4SPTVN1PROD with PROPOSALS
12514 Federal Register / Vol. 77, No. 41 / Thursday, March 1, 2012 / Proposed Rules 

Reporting and recordkeeping 

requirements. 

For the reasons set out above, 21 CFR 

Part 1308 is proposed to be amended as 

follows: 

PART 1308—SCHEDULES OF 

CONTROLLED SUBSTANCES 

1. The authority citation for 21 CFR 

part 1308 continues to read as follows: 

Authority: 21 U.S.C. 811, 812, 871(b), 

unless otherwise noted. 

2. Section 1308.11 is amended by 

redesignating paragraphs (d)(18) 

through (35) as paragraphs (d)(19) 

through (36) and adding a new 

paragraph (d)(18) to read as follows: 

§ 1308.11 Schedule I. 

* * * * * 

(d) * * * 

(18) Cannabimimetic agents 

(i) 1-Butyl-3-(1-naphthoyl)indole (Other names: JWH–073) ............................................................................................................ 7173 

(ii) 5-(1,1-Dimethylheptyl)-2-(3-hydroxycyclohexyl)-phenol (Other names: CP–47,497) .............................................................. 7297 

(iii) 5-(1,1-Dimethyloctyl)-2-(3-hydroxycyclohexyl)-phenol (Other names: Cannabicyclohexanol and CP–47,497 C8 homologue) ............................................................................................................................................................................................... 7298 

(iv) 1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (Other names: JWH–200) .......................................................................... 7200 

(v) 1-Pentyl-3-(1-naphthoyl)indole (Other names: JWH–018 and AM678) ..................................................................................... 7118 

* * * * * 

Dated: February 24, 2012. 

Michele M. Leonhart, 

Administrator. 

[FR Doc. 2012–4982 Filed 2–28–12; 11:15 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF THE TREASURY 

Internal Revenue Service 

26 CFR Part 1 

[REG–157714–06] 

RIN 1545–BG43 

Determination of Governmental Plan 

Status; Correction 

AGENCY: Internal Revenue Service (IRS), 

Treasury. 

ACTION: Notice of public hearing on an 

advance notice of proposed rulemaking; 

correction. 

SUMMARY: This document corrects a 

notice of public hearing on an advance 

proposed rulemaking (REG–157714–06) 

that was published in the Federal 

Register on Friday, February 3, 2012 (77 

FR 5442) relating to the determination 

of governmental plans. 

FOR FURTHER INFORMATION CONTACT: 

Concerning the proposed regulations, 

Pamela Kinard at (202) 622–6060, and 

regarding the submission of public 

comments and the public hearing, Ms. 

Oluwafunmilayo (Funmi) Taylor, at 

(202) 622–7180 (not toll-free numbers). 

SUPPLEMENTARY INFORMATION: 

Background 

The notice of public hearing on an 

advance notice proposed rulemaking 

(REG–133233–08) that is the subject of 

this correction is under section 414(d) of 

the Internal Revenue Code. 

Need for Correction 

As published, REG–157714–06, 

contains errors that may prove to be 

misleading and are in need of 

clarification. 

Correction of Publication 

Accordingly, the publication of the 

notice of public hearing on an advance 

proposed rulemaking (REG–157714–06) 

which was the subject of FR. Doc. 2012– 

2499, is corrected as follows: 

■ 1. On page 5442, column 2, in the 

preamble, under the caption DATES:, line 

four, the language ‘‘Building. The IRS 

must receive outlines’’ is corrected to 

read ‘‘Building. Written or electronic 

comments must be received by June 18, 

2012. The IRS must receive outlines’’ 

■ 2. On page 5442, column 2, in the 

preamble, under the caption 

ADDRESSES:, second paragraph, first 

line, the language ‘‘Mail outlines to 

CC:PA:LPD:PR (REG-’’ is corrected to 

read ’’ Mail submissions and outlines to 

CC:PA:LPD:PR (REG-‘‘. 

LaNita Van Dyke, 

Chief, Publications and Regulations Branch, 

Legal Processing Division, Associate Chief 

Counsel, (Procedure and Administration). 

[FR Doc. 2012–4905 Filed 2–29–12; 8:45 am] 

BILLING CODE 4830–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Coast Guard 

33 CFR Part 117 

[Docket No. USCG–2012–0074, Formerly 

USCG–2011–0314] 

RIN 1625–AA09 

Drawbridge Operation Regulation; 

Hood Canal, WA 

AGENCY: Coast Guard, DHS. 

ACTION: Notice of proposed rulemaking. 

SUMMARY: The Coast Guard proposes to 

modify the drawbridge operating 

regulation for the Hood Canal floating 

drawbridge near Port Gamble. This 

modification would relieve heavy rush 

hour road traffic on State Routes 3 and 

104, by allowing the draws of the bridge 

to not open for maritime traffic during 

afternoon rush hour in the summer 

months. 

DATES: Comments and related material 

must reach the Coast Guard on or before 

April 16, 2012. 

ADDRESSES: You may submit comments 

identified by docket number USCG– 

2012–0074 using any one of the 

following methods: 

(1) Federal eRulemaking Portal: 

http://www.regulations.gov. 

(2) Fax: 202–493–2251. 

(3) Mail: Docket Management Facility 

(M–30), U.S. Department of 

Transportation, West Building Ground 

Floor, Room W12–140, 1200 New Jersey 

Avenue SE., Washington, DC 20590– 

0001. 

(4) Hand delivery: Same as mail 

address above, between 9 a.m. and 

5 p.m., Monday through Friday, except 

Federal holidays. The telephone number 

is 202–366–9329. 

To avoid duplication, please use only 

one of these four methods. See the 

‘‘Public Participation and Request for 

Comments’’ portion of the 

SUPPLEMENTARY INFORMATION section 

below for instructions on submitting 

comments. 

FOR FURTHER INFORMATION CONTACT: If 

you have questions on this rule, call or 

email the Bridge Administrator, Coast 

Guard Thirteenth District; telephone 

206–220–7282 email 

randall.d.overton@uscg.mil. If you have 

questions on viewing or submitting 

material to the docket, call Renee V. 

Wright, Program Manager, Docket 

Operations, telephone 202–366–9826. 

SUPPLEMENTARY INFORMATION: 

Public Participation and Request for 

Comments 

We encourage you to participate in 

this rulemaking by submitting 

comments and related materials. All 


srobinson on DSK4SPTVN1PROD with PROPOSALS